<DOC>
	<DOCNO>NCT02214095</DOCNO>
	<brief_summary>This study first evidence base work evaluate systemic use glucosamine adjunctive therapy close mechanical debridement chronic periodontitis . The use glucosamine sulphate correlate clinical outcome IL1-β level GCF patient moderate advanced chronic periodontitis</brief_summary>
	<brief_title>Glucosamine Periodontal Adjunctive Therapy</brief_title>
	<detailed_description>Targeting inflammatory response may rational approach medical treatment chronic periodontitis . Glucosamine sulphate ( GS ) proven anti-inflammatory action minimal side effect profile . Objectives ; The main objective study evaluate clinically efficacy GS ; novel adjunctive host modulating agent periodontal therapy investigate effect gingival crevicular fluid ( GCF ) level IL-1β . Methods ; Forty patient moderate severe chronic periodontitis ( CP ) include study . They randomly divide two group . Group I ( G1 ) patient ( n=20 ) receive 500 mg GS capsule three time daily 3 month follow full mouth scale root planing ( SRP ) , group II ( G2 ) patient ( n=20 ) receive placebo period follow full mouth SRP . Clinical periodontal parameter GCF IL-1β level analyze baseline 3 month follow therapy .</detailed_description>
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Chronic Periodontitis</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>1. good compliance plaque control instruction follow initial therapy 2. subject contribute single premolar molar tooth interproximal probe depth ≥ 5 mm clinical attachment loss ≥ 4 mm 3. teeth involve vital score 01 mobility 4. availability followup maintenance program ; 1. systemic disease could influence outcome therapy evidence Burket 's Oral Medicine health history questionnaire 2. absence periodontal treatment previous year 3. absence systemic medication antibiotic treatment previous six month 4. absence smoking habit . 5. post menopausal , pregnant breast feed woman exclude participate study . Patients contraindication glucosamine sulphate therapy e.g. , hypersensitivity product 's component inadequate compliance oral hygiene maintenance schedule also exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Cytokines</keyword>
	<keyword>interleukin-1β</keyword>
	<keyword>chronic periodontitis</keyword>
	<keyword>host modulation</keyword>
	<keyword>glucosamine sulphate .</keyword>
</DOC>